Abivax S.A.
Open enrollment across a mixed-phase pipeline
According to ClinicalTrials.gov-derived indexes, Abivax S.A. sits in the upper quartile of US sponsors by registered trial count (#2,085 of 15,742 sponsors by registered trial count).
Abivax S.A.: 6 sponsored US clinical trials, 2 recruiting.
Abivax S.A. sponsors 6 registered US clinical trials on ClinicalTrials.gov, 2 of them currently recruiting, and 3 completed. 3 of these trials are in Phase 3-4 (later-stage) and 3 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Moderately to Severely Active Crohn Disease, with 1 trials.
Upper-quartile sponsor footprint
Abivax S.A. sits in the upper quartile of the sponsor corpus (#2,085 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.
Open and recent trials
6 total, page 1 of 1
Efficacy and Safety of Obefazimod in Subjects With Moderately to Severely Active Crohn's Disease
NCT06456593
ABX196 in Combination With Nivolumab in Patients With Hepatocellular Carcinoma
NCT03897543
ABTECT - Maintenance
NCT05535946
ABTECT-2 - ABX464 Treatment Evaluation for Ulcerative Colitis Therapy -2
NCT05507216
ABTECT-1 - ABX464 Treatment Evaluation for Ulcerative Colitis Therapy -1
NCT05507203
Dose-Ranging Phase 2b Study of ABX464 in Moderate to Severe Ulcerative Colitis
NCT03760003
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 1 |
| Phase 2 | 2 |
| Phase 3 | 3 |
Therapeutic Areas
What is open in the Abivax S.A. pipeline
2 recruiting of 6 indexed (33% open); 3 completed (50%).
Phase mix: 3 late (III/IV) vs 3 early (I/II) (balanced across stages).
Top condition: Moderately to Severely Active Crohn Disease (1 trial), 2 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Abivax S.A.: open-pipeline peers nationwide
Peers matched on 6 registered trials and 33% open enrollment, not the therapeutic-area sidebar.
Abivax S.A. sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 6 trials (± recruiting share)
- 23andMe · 6 trials · 0% recruiting
- Aardvark Therapeutics · 6 trials · 0% recruiting
- Abbisko Therapeutics Co · 6 trials · 67% recruiting
- AbGenomics B.V Taiwan Branch · 6 trials · 0% recruiting
Sponsors near 33% open enrollment (± trial volume)
- Aadi Bioscience · 33% recruiting · 9 trials
- Aaron Cook · 33% recruiting · 3 trials
- Actuated Medical · 33% recruiting · 3 trials
- Adagio Medical · 33% recruiting · 3 trials
Related
What to do with this Abivax S.A. page
6 registered trials is a research-attention snapshot, not an endorsement of Abivax S.A. or any single study.
- 2 of Abivax S.A.'s trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Moderately to Severely Active Crohn Disease is the condition Abivax S.A. studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Moderately to Severely Active Crohn Disease trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Abivax S.A. pipeline card: 6 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.